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Background: HIV-1 infection generates numerous abnormalities in the B cell compartment which can be partly
reversed by antiretroviral therapy. Our aim was to evaluate the effects that re-exposure to HIV antigens might have
on the frequency and functionality of antibody secreting cells (ASC) in patients undergoing structured treatment
interruptions (STI). As re-exposure to viral antigens may also boost the production of (neutralizing) antibodies, we
also assessed the neutralizing activities during STI cycles.
Methods: Retrospective study of 10 patients undergoing 3 cycles of STI with 2 weeks on and 4 weeks off HAART.
ASC frequencies were determined by flow cytometry in samples obtained at the beginning and the end of STI.
Neutralization capacity, total IgG concentration and anti-gp120-IgG titres were evaluated.
Results: As expected, median viral loads were higher at the end of STI compared to on-HAART time points. The
level of CD27 and CD38 expressing ACS followed the same pattern; with ASC being elevated up to 16 fold in some
patients (median increase of 3.5% ± 4.13). Eight out of 10 patients maintained stable total IgG levels during the
study. After purifying IgG fractions from plasma, HIV-neutralizing activity was observed in the two subjects with
highest anti-gp120 titers. In one of these patients the neutralizing activity remained constant while the other
showed elevated neutralizing Ab after first STI and once treatment was reinitiated after the 2nd STI.
Conclusions: Our data suggest that STI and its associated transient increases in viral load drive the frequencies of
ASC in an antigen-specific manner. In some subjects, this re-exposure to autologous virus boosts the presence of
neutralizing antibodies, similar to what is seen after influenza vaccination. STI may not boost clinically beneficial
nAb levels but offers opportunities to isolate nAb producing cells at considerably higher levels than in subjects with
completely suppressed viral replication.
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Clinical parameters to assess HIV disease progression
focus largely on CD4 T cell counts and CD4/CD8 T cell
ratio, yet the B cell compartment of HIV infected
subjects can be severely impacted by chronic HIV infec-
tion as well. This includes hypergammaglobulinaemia
[1,2] and many other alterations in different B cell
subpopulations, such as increased frequencies of imma-
ture transitional B cells, expansion of activated mature
B cells, increased levels of memory B cells with an
exhausted phenotype and a pronounced loss of resting
memory B cells [3-8]. Many of these defects appear to
be at least partly reversible by antiretroviral treatment
and subsequent reduction in antigen viral loads as
declines in hypergammaglobulinaemia, reductions in the
number of HIV-1-specific and non-specific B cells and
the normalization of other B cell subpopulations have
been observed after starting HAART [5,9]. However, the
recovery of memory resting B cells is incomplete despite
prolonged times on HAART and sustained viral suppres-
sion [10,11], leading to a marked deficiency in rapidly
expanding antigen-specific B cells and differentiation
into antibody secreting cells (ASC) after re-exposure to
the cognate antigen [12]. While extensive work has been
conducted in isolating and characterizing the products
of these cells (i.e. neutralizing antibodies), less is known
about their fate in chronic HIV infection and after vac-
cine boosts. Doria-Rose et al. have reported that the fre-
quency of ASCs was higher in HIV-infected patients
than in uninfected donors [13] and a study by Moir et al.
has shown that the peripheral blood B cell populations is
especially enriched in plasmablasts and resting memory
B cell in acute and early stages of HIV infection compared
to chronically HIV infected individuals [14]. These dif-
ferences were maintained after one year on HAART of
both early and chronically HIV-infected individuals and
were associated with a better functional profile of memory
B cells in early treated subjects.
There is currently a great interest in the field to elicit
broadly neutralizing antibodies (NAb) by different HIV-1
vaccine regimens as well as to identify, isolate and
characterize novel monoclonal nAb. There are also en-
couraging results from the RV114 phase III vaccine trial,
which has associated IgG responses against the V1-V2 re-
gion of gp120 and specific viral mutations in these regions
with relative control from infection [15-17]. However,
similar to previous human immunizations with envelope
monomers or trimmers, no (broadly) neutralizing anti-
bodies were induced. In the best of the cases, earlier stud-
ies showed vaccine-induced antibodies able to neutralize
easily neutralizable viral isolates or the vaccine strain only
[18-21]. These limitations highlight the need for the de-
sign of novel immunogens to elicit broadly neutralizing
antibodies, although difficulties related to masked epitopesor tolerance mechanisms induced by self-homologies,
among others, remain [22-24]. Understanding the nature
of virus-specific ASC, their clonal composition and their
induction upon antigen exposure may help to overcome
some of these hurdles and provide important guidance of
how such responses could be induced in vivo.
In an elegant report studying the expansion of
Influenza-virus specific ASC and their neutralizing Ab
production, Wilson and colleagues used Flu vaccination to
re-expose and restimulate the Flu-specific B cell memory
in vivo. Their results showed a rapid, virus-specific expan-
sion of IgG+ plasmablastic B cell (i.e. CD27/CD38-
expressing, antibody secreting cells) that peaked at day 7
after vaccination and which could reach up to 6% of all
peripheral B cells. This significant expansion allowed them
to isolate and characterize more than 50 novel nAb that
were able to bind with high affinity to several Flu vaccine
strains. We here followed the same rational and hy-
pothesized that HIV infected individuals undergoing
structured HAART treatment interruption would be simi-
larly exposed to viral antigen and may boost at least
transiently their HIV-specific ASC response. These ex-
pectations were supported by data showing unusually high
titers of neutralizing antibodies in patients who were
intermittently adherent to therapy and showed brief
viremic periods as well as by earlier studies by Montefiori
et al., where neutralizing antibodies emerged after treat-
ment interruption [25-27]. For the present study, we stud-
ied 10 HIV-1 chronic infected patients who underwent 3
serial structured treatment interruptions (STIs) and tested
whether physiological HIV-antigen re-exposure would
similarly lead to alterations in their ASC populations and
their HIV neutralization capacity.Methods
Ethics statements
The study was approved by the ethics committee of the
Hospital Germans Trias i Pujol. All patients provided
written informed consent for the initial “AUTOVAC-2”
study, which covered further retrospective analyses on
stored samples.Patient selection
Ten subjects were selected among a larger cohort of fifty
HIV-1 positive individuals who were enrolled in a past,
randomized trial (AUTOVAC-2) that aimed to study the
relative benefits of an on/off HAART regimen on viral
control. The STI in this trial consisted of 6 consecutive
cycles of two weeks off treatment followed by 4 weeks
on treatment. The actual duration of periods without
treatment differed among participants as treatment had
to be reinitiated if viral rebound exceeded 10,000 HIV-1
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clusion criteria: having had a viral load (VL) < 50 copies/
ml for at least 2 years, a CD4/CD8 T cell ratio above 0.7
at least during 6 months before the study entry, nadir
CD4 count above 400 cells/mm3 through the whole course
of the disease and current treatment including protease
inhibitors (PIs). The original trial included a control arm
without STI (group A), a group B where STI were
conducted without IL2 administration and a group C where
IL-2 (0.5 mU/BID) was administrated on day 5 after treat-
ment re-introduction for 5 days. For the present study, 5
individuals were selected from group B (no IL2) and group
C (with IL2 after STI) based on sample (plasma, PBMC)
availability for 3 (of the 6) consecutive STI cycles. Main
clinical characteristics are shown in Table 1.
ASC identification
The phenotype and the frequency of ASC were determined
by flow cytometry following a previously described gating
strategy [13], using frozen PBMC samples and the following
monoclonal antibodies conjugated with the indicated
fluorochrome: CD3-allophycocyanin (APC), CD19-fluores-
cein isothiocyanate (FITC), CD27-phycoeritrin-cyanine7
dye (PE-Cy7) and CD38-phycoeritrin (PE) (BD, Barcelona,
Spain). Samples were acquired on an LSRII cytometer and
data analysis was done using the FACSDiva Software v6.1.3
(BD, Barcelona, Spain). Briefly, lymphocytes were identified
by forward and side scatter and B cells gated as CD3 nega-
tive, CD19 positive cells. ASC were identified among CD19
+ population as those cells with high expression of both
CD27 and CD38.
Anti-gp120 IgG determination
The IgG response against gp120 was evaluated by ELISA











1 42 F 5 80
2 54 M 12 33
3 39 M 2 50
4 34 M 15 1200
5 41 F 8 20
6 45 F 7 20
7 51 F 16 20
8 55 M 4 20
9 61 M 5 20
10 51 M 9 20
aM: male; F: female.
bD4T: Stavudine; 3TC:Lamivudine; NFV: Nelfinavir; DDI: Didanosine; ABV: Abacavir; E
c In patient 4 VL value at baseline of 1200 correspond to a blip in viral load as, bothBriefly, recombinant gp120 (NIH AIDS Reference and
Reagent Program) was adsorbed overnight at 4°C on a
96-well Maxisorb plate (Nunc). Then, the plate was
blocked 3 hours at room temperature with 300 ul/well
of blocking buffer containing PBS, 10% fetal bovine
serum (Invitrogen) and 0.05% tween20 (Sigma-Aldrich).
After washing, serial dilutions of the plasma samples,
also in blocking buffer, were incubated overnight at 4°C.
Serial dilutions of the IgGb12 antibody (Polymun) in
blocking buffer were used as standard. The wells were
washed again and 100 ul/well of a HRP-F(ab’)2 goat anti-
human IgG Fc specific (Jackson-Immunoresearch),
diluted 1/25,000 in blocking buffer, was added and
incubated during one hour at room temperature. Finally,
the wells were washed and the chromogenic reaction
developed using OPD substrate and stopped with 4 N
sulphuric acid. Absorbance at 490/620 nm was
measured.Total IgG quantification
The total IgG quantification of plasma samples was
performed by ELISA. Multiabsorbed and purified goat anti-
human IgG-Fc specific F(ab’)2 (Jackson-Immunoresearch)
was used as capture antibody. This antibody was added in
50 μl at 1ug/mL in PBS to each well of a 96-well Maxisorb
plate (Nunc) and incubated overnight at 4°C. After washing
and blocking, plasma samples, diluted in blocking buffer
(see above), were added and incubated during 2 hours at
room temperature. As standard, serial dilutions of a control
plasma pre-quantified by nephelometry was used. After
washing the secondary antibody (see above) was added and
incubated for one more hour. Finally, the chromogenic








1327 1225 D4T + 3TC + NFV NO
801 763 D4T + 3TC + NFV NO
580 548 DDI + 3TC + NFV NO
672 819 ABV + DDI + EFV NO
2702 1061 3TC + NFV + AZT NO
1548 1380 DDI + D4T + NFV YES
956 697 D4T + IDV + 3TC +
RTV
YES
801 744 D4T,3TC,NFV YES
1122 570 IDV + 3TC + AZT YES
987 810 EFV + D4T + 3TC YES
FV: Efavirenz; AZT: Zidovudina; IDV: Indinavir; RTV: Ritonavir.
prior and post values are < 20.
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Plasma samples, inactivated for 1 hour at 56°C, and puri-
fied IgGs were used to evaluate virus-specific neutralization
activity, using the TZM-bl (NIH AIDS Research and
Reference Reagent Program) neutralization assay previ-
ously described by Montefiori et al. [29]. Briefly, three-fold
serial dilutions of plasma samples (starting at a 1/60 dilu-
tion) or purified IgGs (starting at 2 mg/mL) were incubated
in 96-well plates in duplicates for 1 hour with 200TCID50
of two viral strains NL4-3 (NIH AIDS Research and
Reference Reagent Program) and BAL (MRC AIDS
Reagent Program), two clinical isolates AC10 (NIH AIDS
Research and Reference Reagent Program) and SVBP16
and a vesicular stomatitis virus (VSV)-pseudotyped on a
HIV NL4-3 viral backbone included as control for HIV-
Env unspecific neutralization activity. 105 TZM-bl cells
were added per well and incubated for 48 hours at 37°C
and 5% CO2. Luciferase activity was determined using the
Bright-Glo Luciferase Assay System (Promega, Madrid,
Spain) and the luminescence was then quantified in a
luminometer (Fluoroskan Ascet FL, Labsystem). The rela-
tive light units (RLU) obtained were used to calculate the
percentage of neutralization using the formula: %
Neutralization = 1-(R-Rcc/Rvc) × 100; where R = RLU of
the tested plasma, Rcc = RLU of cell alone and Rvc = RLU
of virus alone. The 50% of the inhibitory dose ID50 was
calculated.
IgG purification
Immunoglobulin G was purified from selected samples
using the Ab Spin Trap kit (GE Healthcare, Barcelona,
Spain) according to manufacturer instructions. Briefly,
125 μl of inactivated plasma (1 hour at 56°C) were loaded
into the protein G sepharose column and incubated for
30 min at room temperature, to bind IgG antibodies. The
IgG-depleted plasma fraction was eluted and kept
at −80°C. After extensive washing with PBS, IgGs were
eluted with 0.1 M glycine buffer (pH = 2.8) into tubes
containing neutralizing buffer (1 M TrisHCl pH8.5) to
preserve the activity of acid-labile IgGs. The purified
samples were then buffer-exchanged into PBS and
concentrated using Amicon Ultra-0.5 filters (Millipore,
Barcelona, Spain). Finally, IgG concentrations were
determined by measuring the absorbance at 280 nm in a
spectrophotometer (BioPhotometer, Eppendorf).
Statistical analysis
ASC frequencies and VL levels were expressed as median
values and compared between the three STI, both in the
on-treatment and off-treatment samples using the
Wilcoxon matched pairs test when comparing non-
parametric paired data, or Mann–Whitney test when com-
paring non-parametric unpaired data. Differences were
considered statistically significant if p < 0.05. Relationshipsbetween different variables were assessed using Spearman
rank order non-parametric correlation. All the statistical
analyses were performed with GraphPad Prism v4.
Results
Expansion of ASC frequencies after STIs are driven by HIV
viral loads
In order to examine the effect of STI on ASC populations
and its correlation with changes in HIV viral load, the fre-
quencies of ASC in the peripheral blood were determined
for 10 individuals undergoing 3 cycles of STI. ASCs were
defined among CD19+ B cells as expressing high levels of
CD27 and CD38 as described previously [13]. Samples
were obtained on the day of treatment stop (“on-treat-
ment”) and at the end of the interruption period (“off-
treatment”) for each of the three STI. Five of the 10
patients: patients # 2, 3, 6, 7 and 8 (2 without IL2 [patients
# 2 and 3] and 3 with IL2-treatment [patients # 6, 7 and
8], respectively) showed a rapid viral rebound after treat-
ment interruption to at least 103 viral copies/ml, whereas
the remaining five individuals (patients # 1, 4, 5, 9 and 10)
always maintained their viral loads to <290 viral copies/ml
in all of the interruptions (Figure 1, the missing points in
Patients #2, #4 and #6 for %ASC is due to lack of samples).
The lack of viral rebound in those five patients 2 weeks
after treatment interruptions is in line with a median time
to viral rebound of 14 days seen in previously published
trials assessing STI [30], and thus does not necessarily
imply effective immune control of the virus in these 5
subjects. The addition of IL-2 therapy did not show a sig-
nificant effect on viral control, neither in our selected 5
individuals nor in the overall cohort (with 8 out of 21
patients with IL-2 administration controlling viral rebounds
after 2 weeks off treatment).
In order to examine whether active viral replication
was driving the expansion of ASC, viral copy numbers
per ml and ASC levels were compared between on- and
off-treatment time points. As expected, median viral
loads were always lower in the on-treatment samples
than in the off-treatment time points: median <20 viral
copies/ml [<20-1200] and 615 [<20-452,000] for the first
STI, <20 [<20-654] and 3655 [<20-45900] (p = 0.015) for
the second STI and <50 [<20-482] and 290 [<20-17400]
(p = 0.031), respectively for the third STI (Figure 2a). Al-
though the differences did not reach statistical signifi-
cance, the same tendency was observed for the levels of
peripheral blood ASC, with the median frequency of the
ASC being lower in on-treatment samples than in
samples from off-treatment time points after the second
and the third STI: 0.35% ASC [0.10-1.15] versus 0.25%
[0.10-4.95] for the first STI, 0.35 [0.10-1.40] vs 0.85
[0.30-3.2] for the second STI and 0.30 [0.10-0.70] vs 0.40
[0.15-1.85], respectively for the third STI (Figure 2b). Al-






































































































































































Figure 1 The frequency of ASC was increased after treatment interruption. ASC frequency (measured as % of ASC) and viral load (measured
as Log10HIV-1RNAcopies/ml) dynamics along the study period for the five patients with viral rebound (left panels) and the five patients without
viral rebound (right panels), after treatment interruption are shown. The on-treatment samples correspond to the time of stopping treatment in
each STI, whereas the off-treatment sample correspond to the moment of treatment re-start after the correspondent STI. Intervals when subjects
were on therapy are shaded.










































































Figure 2 Changes in Viral load and ASC frequency in the 3 STIs. (a) Viral load and (b) ASC frequencies are higher in the post-treatment
samples than in the pre-treatment ones after the 3 STI analyzed. The bars represent the median values for each group. Significant differences
are indicated.
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by Doria-Rose et al. indicates that HIV-specific ASC are
not infrequent [13]. However, it is likely that other
specificities also contribute to the changes in total ASC
frequency in the peripheral blood. Across the 10
individuals, the frequency of ASC among total peripheral
blood B cells showed marked fluctuations over the serial
STI, with all individuals increasing their ASC frequency
at least 5–fold at some point during the three on/off
HAART cycles (Figure 1). However, the most significant
changes were observed for individuals who showed a
viral rebound to >1100 viral copies/ml during any of the
interruptions (Figure 1, left hand panels). Indeed, there
is a trend (although no significant) for a direct correl-
ation (r = 0.58; p = 0.08) between the maximal fold
change in the percentage of ASC and the maximal value
of viral load (data not shown). Although larger studies
will be needed to achieve statistical power, these results
suggest that increases in ASC could be driven by viral
antigen load, particularly in subjects who showed strongest
viral reactivation after treatment cessation. This potential
association between increased viral loads and higher levels
of ASC is further supported by the observation that both,
median viral load and median frequency of ASC followed
the same tendency over the course of the three STI: the
median viral load and ASC frequency were higher after the
second STI (3655 copies/mm3 [20–45900] and 0.82%
ASC [0.30-3.25] respectively) than after the first STI (615
[20–452000] for viral load and 0.27% [0.10-4.95] for ASC,
respectively), and lower median values are observed
after the third STI (290 [20–17400] viral load and 0.40%
[0.15-1.85] ACS, respectively) than after the second STI
(data not shown). At the same time, the median percentage
of total B cells remained remarkably stable (9.8% [4.1-14.6]
after the first STI, 9.6% [1.6-19.15] after the second STI and
11.1% [5–14.6] after the third STI, respectively. This
indicates that the changes in ASC were not due to a general
B cell expansion but may reflect fluctuations in the HIV
antigen specific B cell population. None of the above ana-
lyses showed significant differences when the patients were
stratified based on IL2 administration (data not shown), in
line with a lack of a clinical benefit of IL2 administration
that was observed in the overall cohort
STI boost HIV-specific IgG in a subset of patients
As treatment interruptions did not affect the total per-
ipheral B cell numbers and the observed changes in ASC
levels are suggestive of a HIV antigen-specific B cell ex-
pansion, we next determined total IgG levels in serum
samples from all patients at all time-points along the
study period. At baseline (i.e. the first on-treatment sam-
ple in STI 1) seven out of ten patients had normal
(<15 mg/ml) total IgG concentrations in plasma (median
value in mg/ml 12.4 [10.7-21] whereas patients #3, #6and #10 had elevated plasma IgG levels (>15 mg/ml,
Figure 3a, the missing points in Patients #6, both in total
IgG, Figure 3a, and in anti-gp120-specific IgG, Figure 3b,
is due to lack of samples). Among the patients with nor-
mal IgG levels at baseline, two (patients #5 and #7)
showed a transient increase in total IgG after the first
and second STI, respectively, before reaching normal
concentrations again during the third treatment inter-
ruption cycle. To monitor HIV-specific IgG levels, anti-
gp120 titers were evaluated in plasma samples from the
same time points. While anti-gp120 IgG levels were de-
tectable in all subjects at baseline, patients #2 and #7
both maintained particularly high levels of anti-gp120
titers all along the study period (>100 AU IgG anti-
gp120, Figure 3b). Of note, both patients showed highest
levels of anti-gp120 IgG during the second STI, at times
when their rebounding virus also reached maximal levels
(Figure 4a and Figure 2). Together, the data indicate that
the majority of the patients (7 out of 10, 70%) did not
significantly increase their total IgG levels during STI
cycles, suggesting that viral reactivation was not indu-
cing a pronounced hypergammgobulianemia.
Ig-mediated neutralization activity can be increased
after STI
To assess whether increases in HIV-specific IgG titers dur-
ing STI extend to neutralizing Ab as well, the production
of neutralization antibodies (NAb) was determined in all
10 subjects for all three STI cycles. Neutralization assays
were carried out using two laboratory viral strains NL4-3
and BAL and two clinical viral isolates (AC10 and
SVBP16) in the TZM-bl cell line based neutralization
assay [29]. Five out of ten patients presented low or no
neutralization activity (<200 ID50 value) and one patient
presented median neutralization activity (200–1000 ID50
value) (data not shown). The remaining four patients had
high neutralization titers (>1000 ID50 value) in at least one
of the samples tested (Figure 4, left hand panels). Of note,
those patients were also the ones infected for longest
(Table 1, 9–16 years, p = 0.0095), in accordance with pre-
vious publications from several groups where plasma
neutralization activities increased with time since infection
[31,32]. All four of these subjects showed effective
neutralization of at least the lab strains NL4-3 and BAL,
with patients #4 and #10 showing an even more robust
neutralization of the viral isolates AC10 and SVBP16 in
some of the samples (Figure 4, left hand panels). As this
activity was mainly seen in samples at the beginning of the
treatment interruption (i.e. on-treatment) it may reflect
the presence of residual antiretroviral drugs, particularly
Efavirenz, which has been described to have a long plasma
half-life [33-37]. Indeed, these two patients were the only
ones who were receiving Efavirenz as part of their anti-













































Patient6 Patient7 Patient8 Patient9 Patient10
Patient3 Patient4 Patient5
Figure 3 Total IgG levels and anti-gp120 titers are shown for all patients along the study period. (a) Total IgG levels with the normal
cut-off set at 15 mg/ml and (b) anti-gp120 titers are shown.
Llano et al. Journal of Translational Medicine 2013, 11:48 Page 8 of 13
http://www.translational-medicine.com/content/11/1/48

















Patient # 2 vs NL-43
Patient # 4 vs NL43
Patient # 7 vs NL43

















































ON-TTo OFF-TTo ON-TTo OFF-TTo ON-TTo OFF-TTo
IgG purified fraction at 200 ug/ml 1/60 dilution of IgG negative elute fraction
Patient # 2








































ON-TTo OFF-TTo ON-TTo OFF-TTo ON-TTo OFF-TTo
Figure 4 (See legend on next page.)
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Figure 4 Neutralization activity. Neutralization activity (ID50) against NL4-3, BAL, AC10 and SVBP16 in inactivated plasma samples of 4 patients
are depicted longitudinally (Left panels). The percentage of neutralization in the IgG purification fraction (200 μg/ml) and in the negative fraction
(1/60 dilution) are longitudinally depicted for the 4 patients against NL4-3 (Right panels). In patients #4 and #10 dashed line represents theoretical
union between the percentages of neutralization measured in the on-treatment samples with the non-measured ones in off-treatment samples.
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plasma. Both, the IgG purified fraction and the negative
elute fraction were tested in neutralization assays against
NL4-3 and VSV-HIV-pseudotyped virus. As suspected, the
IgG-depleted elute (used as a 1/60 dilution) was able to in-
hibit viral replication completely (100% of neutralization ac-
tivity) for NL4-3 virus. The purified fraction tested at 200
ug/ml reached around the 80% of neutralization for NL4-3
virus in these two patients. Thus, the strong neutralization
activity seen in unpurified plasma was likely largely due to
residual antiretroviral in samples taken on the day of treat-
ment stop. In contrast, for patients #2 and #7, the
neutralization capacity was contained in the purified IgG
fraction (80% of neutralization capacity against NL4-3 when
tested at 200 ug/ml) and not in the IgG-depleted elute
(16%-54% when tested at a 1/60 dilution). Of note, all
neutralization activities observed in the purified IgG
fractions were HIV-specific, since no neutralization was
seen when using VSV-peudotyped NL4-3 virus as negative
control (data not shown).Discussion
The presence of HIV-specific neutralizing antibodies has
been associated in several studies with at least partial
viral control after treatment interruption [25,27]. How-
ever, the frequency at which infected individuals are able
to regain effective nAb activity after STI varies widely
and may be impacted by the general and B cell-specific
immune status of the subject undergoing STI. To our
knowledge, the present report is the first study that spe-
cifically addresses the effects of STI on the frequency of
antibody secreting cells and their production of nAb. In
the case of Influenza vaccination in healthy, HIV unin-
fected, individuals the exposure to vaccine-derived viral
antigen has been shown to lead to a rapid expansion of
ASC that also produced high titers of nAb [38]. We
hypothesized that STI in HIV infection could mimic
such antigen exposure and thus aimed to use existing
samples from a larger, past STI trial to characterize the
effects of STI on ASC frequency and nAb activity. The
use of retrospective samples was needed as the STI/self-
vaccination approaches have not been holding their ini-
tial promise to lead to effective in vivo viral control and
are nowadays generally limited to “analytical STI” in the
setting of therapeutic interventions. With the use of
retrospective samples however, the present study wasseverely limited to the existing time points and patients
from which specimens were collected.
In previous studies, with immunizations using a Salmon-
ella typhi oral vaccine, ASC were found to appear in the
peripheral blood a few days after vaccination, reaching the
highest levels on day 7 and were again undetectable 2 weeks
after vaccination [39]. The same kinetics were also seen in
the study by Wrammert et al. using influenza vaccination
where influenza-specific ASCs in peripheral blood peaked
at day 7 post immunization, returning to basal levels by
day 14 after vaccination [38]. The trial, from which
samples were available for the present study, sampled per-
ipheral blood after 2 weeks of treatment interruption, put-
ting our analyses potentially on the far end of ASC
reactivation. Probably, the peak in ASC may not be as
early for instance as after a (Flu) vaccination where
antigen is given at once and generally in healthy
individuals. Furthermore, the individuals undergoing treat-
ment interruptions are HIV infected and at least partly
immune compromised subjects, for which rapid and
strong changes in ASC may actually come rather as a sur-
prise. Despite this concern, our data clearly indicate that
ASC are expanded after re-exposure to HIV antigens, par-
ticularly in subjects with clinically detectable (>1100 cop-
ies/ml) viral rebounds within these two weeks. We can
however not exclude that subjects with subclinical viral re-
bound also drove their ASC populations; possibly to a
lower extend and which may not be detectable anymore at
14 days post treatment interruption. On the other hand,
and in contrast to the immediate availability of antigen
upon for instance Flu vaccination, re-exposure to
sufficient quantities of the autologous HIV may require a
few days of viral replication (and reduction of antiretro-
viral drugs) to reach effective stimulatory levels and could
thus possibly delay their emergence in the peripheral
blood. Nevertheless, the quite rapid kinetics of ASC
fluctuations described in the vaccination studies above as
well as HIV-related STI setting are further documented by
the return of ASC levels to basal values within only the 4 -
weeks of on-treatment cycles. While these kinetics and
our data presented here suggest that these fluctuations are
driven by the expansion of HIV-specific B cells, our data
can not document this directly since our assays were not
geared towards the detection of HIV-specific ASC. How-
ever, in previous studies by Doria-Rose et al., B cells with a
CD3-CD19+CD20-/lowCD27hiCD38hi plasmablast pheno-
type were indeed increased in HIV infection and accounted
for the vast majority of HIV-specific ASC (up to 92% of gp-
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IgG levels seen in most of our patients during on-off treat-
ment cycles strongly suggests that STI and subsequent viral
reactivation drive preferentially the expansion of HIV-
specific ASC. Given the B cell phenotype and the rapid kin-
etics, it is also likely that the increased B cell responses were
due to a reactivation of pre-existing memory B cells rather
than stimulation of newly generated ASC.
When assessing gp120 specific Ab production upon
STI, we did not observe a correlation between ASC fre-
quencies and anti-gp120 IgG levels in the plasma. As all
patients showed detectable anti-gp120 IgG levels in the
baseline sample, only mild increases in their concentration
upon STI may have been masked by anti-gp120 IgG
produced by long-term memory plasma cells that continu-
ously produce antibodies without the need of antigen ex-
posure [40]. Alternatively, IgG of other HIV-specificities
not assessed here (including gp41 specific responses)
could have been produced, making us miss a potential
correlation between increases in HIV-specific ASC levels
and total anti-viral IgG. The same limitation applies when
the gp120 levels were compared to neutralization activ-
ities. After controlling for residual antiretroviral drugs in
the plasma at times when treatment was interrupted, only
the two subjects with highest gp120 IgG levels showed
neutralization activity. It remains thus unclear whether
additional specificities may have contributed to this activ-
ity aside from the gp120 specific cells and what the frac-
tion of non-neutralizing IgG among the anti-gp120
fraction was [13,41-43].
Overall, 20% (2/10) of the patients showed neutralizing
activity in purified IgG fractions. These subjects were
among the 5 individuals who showed robust reactivation
of their virus during all STI cycles and who had a reduced
CD4 T cell count at the start of first STI (median CD4
count 801/ul) compared to the five subjects that did not
show consistent viral reactivation (median CD4 count
1122/ul). Of note, the fluctuations in neutralization activ-
ities are not uniformly paralleled in these two subjects,
possibly reflecting variable parameters that govern their
kinetics, including growth kinetics of autologous virus,
existing T-helper cell immunity (especially follicular helper
CD4 T cell responses that are needed for B cell differenti-
ation into plasma cells) and the presence of memory B
cells in lymph nodes [44-47]. In addition, the sustained
presence of memory B cell populations with low levels of
Foxo3a and TRAIL-mediated apoptosis has been associated
with relative viral control and may have further impacted
ASC expansion upon STI [48]. Regardless of these
limitations, STI may offer a window of opportunity to gain
access to samples with highly enriched frequencies of HIV-
specific ASC in at least some individuals, especially with
the identification of additional parameters that can predict
their presence reliably.Conclusions
In summary, our results suggest that antigen re-exposure
after STI can lead to substantial increases in the frequencies
of ASC and, at least in some patients, this increase is
associated with the enhancement of HIV-specific IgG-
mediated neutralizing activities. While additional factors
that limit such a recovery in neutralizing activity to few
individuals remain to be identified, analytical STI in thera-
peutic vaccine trials or the screening of extensive sample
banks from past STI trials may offer opportunities to isolate
ASC producing nAb at significantly elevated levels, facilitat-
ing the identification and characterization of new nAb
against HIV, and thereby providing crucial information for
future HIV vaccine design.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CB conceived the experiments, participated in its design and collaborated to
draft and to write the manuscript. ALL designed the experiments, carried out
the flow cytometry, and the IgG purifications assays, performed the statistical
analysis, analyzed the data and wrote the manuscript. JC carried out the
ELISA assays and participated in the data interpretation. JB participated in
experiments design, data discussion and manuscript revision. EY, VS, BM and
BC helped in data discussion and manuscript revision. LR helped in selecting
the samples and in drafting the manuscript. SM and EG carried out the
neutralization assays and helped in their analysis. All authors read and
approved the final manuscript.
Acknowledgments
This work was supported by HIVACAT, the Catalan Program for the
development of therapeutic and preventive HIV vaccines, which is jointly
funded by Esteve Laboratories, La Caixa Foundation and the Catalan
Government.
Author details
1Irsicaixa AIDS Research Institute – HIVACAT, Hospital Universitari Germans
Trias y Pujol, Badalona, Spain. 2Fundacio Lluita contra la SIDA, Hospital
Universitari Germans Trias y Pujol, Badalona, Spain. 3Universitat Autònoma de
Barcelona, Hospital Universitari Germans Trias y Pujol, Badalona, Spain.
4Retrovirology and Viral Immunopathology Laboratory, IDIBAPS, HIVACAT,
Hospital Clínic, University of Barcelona, Barcelona, Spain. 5Institut
d’Investigació en Ciencies de la Salut Germans Trias i Pujol, IGTP, Badalona,
Spain. 6Institució Catalana de Reserca y Estudis Avançats (ICREA), Barcelona,
Spain.
Received: 5 December 2012 Accepted: 19 February 2013
Published: 22 February 2013
References
1. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS: Abnormalities
of B-cell activation and immunoregulation in patients with the acquired
immunodeficiency syndrome. N Engl J Med 1983, 309:453–458.
2. Mizuma H, Zolla-Pazner S, Litwin S, El-Sadr W, Sharpe S, Zehr B, Weiss S,
Saxinger WC, Marmor M: Serum IgD elevation is an early marker of B cell
activation during infection with the human immunodeficiency viruses.
Clin Exp Immunol 1987, 68:5–14.
3. Malaspina A, Moir S, Ho J, Wang W, Howell ML, O’Shea MA, Roby GA, Rehm
CA, Mican JM, Chun TW, Fauci AS: Appearance of immature/transitional B
cells in HIV-infected individuals with advanced disease: correlation with
increased IL-7. Proc Natl Acad Sci USA 2006, 103:2262–2267.
4. Malaspina A, Moir S, Chaitt DG, Rehm CA, Kottilil S, Falloon J, Fauci AS:
Idiopathic CD4+ T lymphocytopenia is associated with increases in
immature/transitional B cells and serum levels of IL-7. Blood 2007,
109:2086–2088.
Llano et al. Journal of Translational Medicine 2013, 11:48 Page 12 of 13
http://www.translational-medicine.com/content/11/1/485. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, Hurley A, Cao Y,
Markowitz M, Ho DD, Moore JP: HIV-1 antigen-specific and -nonspecific B
cell responses are sensitive to combination antiretroviral therapy. J Exp
Med 1998, 188:233–245.
6. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu
S, Adelsberger J, Lapointe R, Hwu P, et al: HIV-1 induces phenotypic and
functional perturbations of B cells in chronically infected individuals.
Proc Natl Acad Sci USA 2001, 98:10362–10367.
7. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O’Shea MA, Roby G, Kottilil
S, Arthos J, Proschan MA, et al: Evidence for HIV-associated B cell
exhaustion in a dysfunctional memory B cell compartment in HIV-
infected viremic individuals. J Exp Med 2008, 205:1797–1805.
8. Bussmann BM, Reiche S, Bieniek B, Krznaric I, Ackermann F, Jassoy C: Loss of
HIV-specific memory B-cells as a potential mechanism for the
dysfunction of the humoral immune response against HIV. Virology 2009,
397:7–13.
9. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O’Shea MA, Roby G, Mican
JM, Kottilil S, Chun TW, et al: Normalization of B cell counts and
subpopulations after antiretroviral therapy in chronic HIV disease. J Infect
Dis 2008, 197:572–579.
10. De Milito A, Morch C, Sonnerborg A, Chiodi F: Loss of memory (CD27) B
lymphocytes in HIV-1 infection. AIDS 2001, 15:957–964.
11. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, Atlas A,
Hejdeman B, Kroon FP, Lopalco L, Nilsson A, Chiodi F: Loss of memory B
cells impairs maintenance of long-term serologic memory during HIV-1
infection. Blood 2006, 108:1580–1587.
12. Tangye SG, Tarlinton DM: Memory B cells: effectors of long-lived immune
responses. Eur J Immunol 2009, 39:2065–2075.
13. Doria-Rose NA, Klein RM, Manion MM, O’Dell S, Phogat A, Chakrabarti B,
Hallahan CW, Migueles SA, Wrammert J, Ahmed R, et al: Frequency and
phenotype of human immunodeficiency virus envelope-specific B cells
from patients with broadly cross-neutralizing antibodies. J Virol 2009,
83:188–199.
14. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, Posada JG, Kardava
L, O’Shea MA, Kottilil S, et al: B cells in early and chronic HIV infection:
evidence for preservation of immune function associated with early
initiation of antiretroviral therapy. Blood 2010, 116:5571–5579.
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris
R, Premsri N, Namwat C, de Souza M, Adams E, et al: Vaccination with
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med
2009, 361:2209–2220.
16. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM,
Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al: Immune-correlates
analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012,
366:1275–1286.
17. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T,
Decamp AC, Carrico C, Menis S, Magaret CA, et al: Increased HIV-1 vaccine
efficacy against viruses with genetic signatures in Env V2. Nature 2012,
490:417–420.
18. Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D’Souza P,
Rodriguez-Chavez IR, DeCamp A, Giganti M, et al: Magnitude and breadth
of a nonprotective neutralizing antibody response in an efficacy trial of
a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202:595–605.
19. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH,
Clements ML, Dolin R, Graham BS, Gorse GJ, et al: Immunization with
envelope subunit vaccine products elicits neutralizing antibodies against
laboratory-adapted but not primary isolates of human
immunodeficiency virus type 1. The national institute of allergy and
infectious diseases AIDS vaccine evaluation group. J Infect Dis 1996,
173:340–348.
20. Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El
Habib R, Klein M, Lazzarin A, et al: Immunization with recombinant
canarypox vectors expressing membrane-anchored glycoprotein 120
followed by glycoprotein 160 boosting fails to generate antibodies
that neutralize R5 primary isolates of human immunodeficiency virus
type 1. AIDS Res Hum Retroviruses 2000, 16:2019–2035.
21. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege
AM, Tartaglia J, Cox WI, McNamara J, et al: Induction of immune responses
to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant
vaccines in uninfected volunteers. NIAID AIDS vaccine evaluation group.
AIDS 1998, 12:2407–2415.22. Kwong PD, Mascola JR, Nabel GJ: Rational design of vaccines to elicit
broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med
2012, 1:a007278.
23. Mascola JR, Montefiori DC: The role of antibodies in HIV vaccines.
Annu Rev Immunol 2010, 28:413–444.
24. McElrath MJ, Haynes BF: Induction of immunity to human
immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542–554.
25. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES: Neutralizing
antibodies associated with viremia control in a subset of individuals
after treatment of acute human immunodeficiency virus type 1
infection. J Virol 2001, 75:10200–10207.
26. Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F,
Walker BD, Rosenberg ES: Viremia control despite escape from a rapid
and potent autologous neutralizing antibody response after therapy
cessation in an HIV-1-infected individual. J Immunol 2003,
170:3906–3914.
27. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, Richman D, Hurley A,
Markowitz M, Moore JP: The effect of highly active antiretroviral therapy
on binding and neutralizing antibody responses to human
immunodeficiency virus type 1 infection. J Infect Dis 2000, 182:945–949.
28. Sanchez-Palomino S, Massanella M, Carrillo J, Garcia A, Garcia F, Gonzalez N,
Merino A, Alcami J, Bofill M, Yuste E, et al: A cell-to-cell HIV transfer assay
identifies humoral responses with broad neutralization activity.
Vaccine 2011, 29:5250–5259.
29. Montefiori DC: Measuring HIV neutralization in a luciferase reporter gene
assay. Methods Mol Biol 2009, 485:395–405.
30. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E,
Sirera G, Tural C, Clotet B: Structured treatment interruption in chronically HIV-
1 infected patients after long-term viral suppression. AIDS 2000, 14:397–403.
31. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H: Prevalence of
cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with
rapid or slow disease progression. AIDS 2009, 23:2405–2414.
32. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L:
Characteristics of the earliest cross-neutralizing antibody response to
HIV-1. PLoS Pathog 2011, 7:e1001251.
33. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford
DB, Marzolini C, Fletcher CV, Tashima KT, et al: Pharmacogenetics of
plasma Efavirenz exposure after treatment discontinuation: an adult
AIDS clinical trials group study. Clin Infect Dis 2006, 42:401–407.
34. Dreyer K, Kallas EG, Planelles V, Montefiori D, McDermott MP, Hasan MS,
Evans TG: Primary isolate neutralization by HIV type 1-infected patient
sera in the era of highly active antiretroviral therapy. AIDS Res Hum
Retroviruses 1999, 15:1563–1571.
35. Burrer R, Spiridon G, Einius-Haessig S, Richert S, Salmon-Ceron D, Pancino G,
Aubertin AM, Moog C: Efavirenz in plasma from HIV-infected patients
does not directly block reverse transcriptase activity in cell-free assays
but inhibits HIV replication in cellular assays. AIDS Res Hum Retroviruses
2006, 22:865–869.
36. Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, Merino-Mansilla
A, Ferreira CB, Perez I, Gonzalez N, Alvarez A, Alcocer-Gonzalez JM, Garcia F,
et al: Broadly cross-neutralizing antibodies in HIV-1 patients with
undetectable viremia. J Virol 2011, 85:5804–5813.
37. Burrer R, Salmon-Ceron D, Richert S, Pancino G, Spiridon G, Haessig S,
Roques V, Barre-Sinoussi F, Aubertin AM, Moog C: Immunoglobulin
G (IgG) and IgA, but also nonantibody factors, account for in vitro
neutralization of human immunodeficiency virus (HIV) type 1 primary
isolates by serum and plasma of HIV-infected patients. J Virol 2001,
75:5421–5424.
38. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY,
Mays I, Garman L, Helms C, et al: Rapid cloning of high-affinity human
monoclonal antibodies against influenza virus. Nature 2008, 453:667–671.
39. Kantele A: Peripheral blood antibody-secreting cells in the evaluation of
the immune response to an oral vaccine. J Biotechnol 1996, 44:217–224.
40. Slifka MK, Ahmed R: Long-lived plasma cells: a mechanism for
maintaining persistent antibody production. Curr Opin Immunol 1998,
10:252–258.
41. Palker TJ, Matthews TJ, Clark ME, Cianciolo GJ, Randall RR, Langlois AJ, White
GC, Safai B, Snyderman R, Bolognesi DP, et al: A conserved region at the
COOH terminus of human immunodeficiency virus gp120 envelope
protein contains an immunodominant epitope. Proc Natl Acad Sci USA
1987, 84:2479–2483.
Llano et al. Journal of Translational Medicine 2013, 11:48 Page 13 of 13
http://www.translational-medicine.com/content/11/1/4842. Gnann JW Jr, Schwimmbeck PL, Nelson JA, Truax AB, Oldstone MB:
Diagnosis of AIDS by using a 12-amino acid peptide representing an
immunodominant epitope of the human immunodeficiency virus. J Infect
Dis 1987, 156:261–267.
43. Moore JP, Cao Y, Ho DD, Koup RA: Development of the anti-gp120
antibody response during seroconversion to human immunodeficiency
virus type 1. J Virol 1994, 68:5142–5155.
44. Crotty: Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011,
29:621–663.
45. Klatt NR, Vinton CL, Lynch RM, Canary LA, Ho J, Darrah PA, Estes JD, Seder
RA, Moir SL, Brenchley JM: SIV infection of rhesus macaques results in
dysfunctional T- and B-cell responses to neo and recall Leishmania
major vaccination. Blood 2011, 118:5803–5812.
46. Croty: Designing Vaccines: Follicular Helper CD4 cells and their roles in
generating neutralizing antibody responses. Abstract #28. Keystone Symposia
on HIV Vaccines (X5). Keystone Colorado: 2012.
47. Kwa, Sadagopal, Hong, Basu, Lai, et al: CD40L enhances CD4 T follicular helper
responses and promotes the development of B cell follicles and germinal
centers in lymph nodes. Abstract # 221. Keystone Symposia on HIV Vaccines
(X5), Abstr. 221. Keystone Symposia, HIV Vaccines 2012. Keystone Colorado:
2012. http://www.keystonesymposia.org.
48. van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, Filali-
Mouhim A, Dupuy FP, Procopio FA, Chomont N, et al: Loss of memory B
cells during chronic HIV infection is driven by Foxo3a- and TRAIL-
mediated apoptosis. J Clin Invest 2011, 121:3877–3888.
doi:10.1186/1479-5876-11-48
Cite this article as: Llano et al.: Expansion of antibody secreting cells
and modulation of neutralizing antibody activity in HIV infected
individuals undergoing structured treatment interruptions. Journal of
Translational Medicine 2013 11:48.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
